Halberd Corporation (HALB)
OTCMKTS · Delayed Price · Currency is USD
0.0013
-0.0000 (-2.99%)
At close: Dec 5, 2025
Halberd Revenue
Halberd had revenue of $1.22K in the quarter ending April 30, 2022, with 6.38% growth. This brings the company's revenue in the last twelve months to $6.94K. In the fiscal year ending July 31, 2021, Halberd had annual revenue of $5.24K.
Revenue (ttm)
6.94K
Revenue Growth
n/a
P/S Ratio
132.51
Revenue / Employee
2.31K
Employees
3
Market Cap
919.49K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jul 31, 2021 | 5.24K | - | - |
| Jul 31, 2020 | - | - | - |
| Jul 31, 2011 | 80.08K | 46.68K | 139.74% |
| Jul 31, 2010 | 33.40K | 25.49K | 322.00% |
| Jul 31, 2009 | 7.92K | 900.00 | 12.83% |
| Jul 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |
Halberd News
- 4 weeks ago - Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University - GlobeNewsWire
- 2 months ago - Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment - GlobeNewsWire
- 1 year ago - Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction - GlobeNewsWire
- 1 year ago - Halberd's Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill - Accesswire
- 1 year ago - Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans - Accesswire
- 1 year ago - Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract - Accesswire
- 1 year ago - Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing - Accesswire
- 1 year ago - Halberd's Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on "The Street Reports Podcast" - Accesswire